A
Alexander F. Lovejoy
Researcher at Stanford University
Publications - 20
Citations - 3245
Alexander F. Lovejoy is an academic researcher from Stanford University. The author has contributed to research in topics: Lung cancer & RNA. The author has an hindex of 10, co-authored 17 publications receiving 2436 citations.
Papers
More filters
Journal ArticleDOI
Circulating Tumor DNA Analysis during Radiation Therapy for Localized Lung Cancer Predicts Treatment Outcome
Aadel A. Chaudhuri,Alexander F. Lovejoy,Jacob J. Chabon,Aaron M. Newman,Henning Stehr,D.J. Merriott,Justin N. Carter,Tej D. Azad,Sukhmani K. Padda,Michael F. Gensheimer,Heather A. Wakelee,Joel W. Neal,Billy W. Loo,Ash A. Alizadeh,Maximilian Diehn +14 more
Journal ArticleDOI
Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma
David M. Kurtz,Florian Scherer,Aaron M. Newman,Alexander F. Lovejoy,Daniel M. Klass,Jacob J. Chabon,Sanjiv S. Gambhir,Maximilian Diehn,Ash A. Alizadeh +8 more
TL;DR: Given its high specificity and large dynamic range, ctDNA provides an opportunity to monitor the dynamics of therapeutic response in patients with DLBCL, and a multi-compartmental ordinary-differential equation model of tumor dynamics capturing tumor volume, cTDNA, and the effect of chemotherapy is developed.
Journal ArticleDOI
Risk profiling of patients with relapsed/refractory diffuse large B-cell lymphoma by measuring circulating tumor DNA
Alex F. Herrera,Sam Tracy,Brandon Croft,Stephen Opat,Jill Ray,Alexander F. Lovejoy,L. Musick,Joseph N. Paulson,Laurie H. Sehn,Yanwen Jiang +9 more
TL;DR: The level of baseline ct DNA correlated with PFS and OS in patients with R/R DLBCL receiving pola plus BR or BR alone and patients with a CR had a significantly greater median decrease in ctDNA levels at end of treatment than patients without a CR.
Journal ArticleDOI
Analysis of circulating tumor DNA in localized lung cancer for detection of molecular residual disease and personalization of adjuvant strategies.
Aadel A. Chaudhuri,Jacob J. Chabon,Alexander F. Lovejoy,Aaron M. Newman,Henning Stehr,Tej D. Azad,Justin N. Carter,D.J. Merriott,Chih Long Liu,David M. Kurtz,Jonathan C. Dudley,Sukhmani K. Padda,Joseph B. Shrager,Joel W. Neal,Heather A. Wakelee,Billy W. Loo,Ash A. Alizadeh,Maximilian Diehn +17 more
TL;DR: This clinical trial aimed at identifying patients with residual disease following curative intent therapy with localized non-small cell lung cancer (NSCLC) and aims to provide real-time information on the progression-free survival and quality of life of these patients.
Proceedings ArticleDOI
Abstract 1034: Role of KEAP1/NRF2 and TP53 mutations in lung squamous cell carcinoma development and radiation resistance
Youngtae Jeong,Ngoc Hoang,Henning Stehr,Alexander F. Lovejoy,Andrew J. Gentles,Aadel A. Chaudhuri,Billy W. Loo,Ash A. Alizadeh,Maximilian Diehn +8 more
TL;DR: Novel, clinically relevant murine LSCC models driven by inactivation of Trp53 with or without Keap1 are described and KEAP1/NRF2 mutations are identified as predictive biomarkers that could be used for personalization of therapeutic strategies for NSCLCs, and likely other cancers in which they are recurrently mutated.